Pravastatin experience in elderly and non-elderly patients

Area of Science:

• Cardiology
• Pharmacology
• Geriatrics

Background:

• Elevated cholesterol is linked to coronary heart disease (CHD) morbidity and mortality.
• Lowering cholesterol is a key strategy for CHD prevention.
• Elderly individuals represent a significant population at risk for hypercholesterolemia and CHD.

Purpose of the Study:

• To evaluate the safety and efficacy of pravastatin in elderly (≥65 years) versus non-elderly hypercholesterolemic patients.
• To assess the long-term effectiveness and tolerability of pravastatin in different age groups.
• To compare pravastatin's lipid-lowering effects and adverse event profiles across age demographics.

Main Methods:

• Pooled analysis of individual patient data from six double-blind, randomized, multicenter studies.
• Comparison of pravastatin's effects in elderly (≥65 years) and non-elderly patient cohorts.
• Assessment of lipid profiles (total cholesterol, LDL, HDL, triglycerides) and adverse events over short-term (8-16 weeks) and long-term (≥24 months) study periods.

Main Results:

• Pravastatin (20 or 40 mg daily) significantly reduced total cholesterol (19-25%) and LDL cholesterol (25-33%), with a modest increase in HDL cholesterol (5-10%).
• Lipid-lowering effects and improvements were sustained long-term (over 24 months) in both elderly and non-elderly patients.
• Incidences of adverse drug events and laboratory abnormalities were similar between elderly and non-elderly groups, with very low discontinuation rates (<1% short-term, 0.4% long-term pravastatin group).

Conclusions:

• Pravastatin is a safe and effective HMG CoA reductase inhibitor for long-term management of hypercholesterolemia in elderly patients.
• The drug demonstrates comparable efficacy and tolerability in elderly and non-elderly populations.
• Pravastatin offers a convenient once-daily dosing regimen for cholesterol management in older adults.